ZA984084B - Use of thiazolidinedione derivatives in the treatment of polycistic ovary syndrome gestational diabetes and disease states at risk for progressing to noninsulindependent diabetes mellitus - Google Patents

Use of thiazolidinedione derivatives in the treatment of polycistic ovary syndrome gestational diabetes and disease states at risk for progressing to noninsulindependent diabetes mellitus

Info

Publication number
ZA984084B
ZA984084B ZA984084A ZA984084A ZA984084B ZA 984084 B ZA984084 B ZA 984084B ZA 984084 A ZA984084 A ZA 984084A ZA 984084 A ZA984084 A ZA 984084A ZA 984084 B ZA984084 B ZA 984084B
Authority
ZA
South Africa
Prior art keywords
progressing
risk
treatment
disease states
ovary syndrome
Prior art date
Application number
ZA984084A
Other languages
English (en)
Inventor
Tammy Antonucci
Dean Lockwood
Rebecca Norris
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA984084B publication Critical patent/ZA984084B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA984084A 1997-05-15 1998-05-14 Use of thiazolidinedione derivatives in the treatment of polycistic ovary syndrome gestational diabetes and disease states at risk for progressing to noninsulindependent diabetes mellitus ZA984084B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/856,987 US5874454A (en) 1993-09-15 1997-05-15 Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus

Publications (1)

Publication Number Publication Date
ZA984084B true ZA984084B (en) 1998-11-20

Family

ID=25324901

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA984084A ZA984084B (en) 1997-05-15 1998-05-14 Use of thiazolidinedione derivatives in the treatment of polycistic ovary syndrome gestational diabetes and disease states at risk for progressing to noninsulindependent diabetes mellitus

Country Status (14)

Country Link
US (1) US5874454A (is)
EP (1) EP0981346A1 (is)
JP (1) JP2001525827A (is)
KR (1) KR20010012556A (is)
AU (1) AU731690B2 (is)
BR (1) BR9809120A (is)
CA (1) CA2282473A1 (is)
HU (1) HUP0003397A3 (is)
IL (1) IL132125A0 (is)
IS (1) IS5177A (is)
NO (1) NO995549L (is)
PL (1) PL336764A1 (is)
WO (1) WO1998051305A1 (is)
ZA (1) ZA984084B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
WO2016065326A2 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
RU2665969C1 (ru) * 2017-05-04 2018-09-05 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ лечения синдрома поликистозных яичников

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
DE69100282T3 (de) * 1990-02-09 2001-01-11 Pharmacia & Upjohn Co., Kalamazoo Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
CA2111096C (en) * 1991-06-25 1997-01-14 Steven Wayne Goldstein Thiazolidinedione hypoglycemic agents
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
RU2195282C2 (ru) * 1993-09-15 2002-12-27 Санкио Компани Лимитед Применение тиазолидиндионов для предотвращения или отдаления наступления инсулиннезависимого сахарного диабета (niddm)

Also Published As

Publication number Publication date
IL132125A0 (en) 2001-03-19
KR20010012556A (ko) 2001-02-15
EP0981346A1 (en) 2000-03-01
US5874454A (en) 1999-02-23
BR9809120A (pt) 2000-08-01
JP2001525827A (ja) 2001-12-11
AU731690B2 (en) 2001-04-05
HUP0003397A3 (en) 2002-02-28
WO1998051305A1 (en) 1998-11-19
PL336764A1 (en) 2000-07-17
IS5177A (is) 1999-09-10
HUP0003397A2 (hu) 2002-01-28
CA2282473A1 (en) 1998-11-19
NO995549D0 (no) 1999-11-12
NO995549L (no) 1999-11-12
AU7494998A (en) 1998-12-08

Similar Documents

Publication Publication Date Title
HUP0003876A3 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
IL213041A0 (en) Use of hypoglycemic agent for treating impaired glucose metabolism
AP9901719A0 (en) Treatment of diabetes with thiazolidinedione and metormin
HK1045111A1 (en) (3-Trihalomethylphenoxy) (4-halophenyl) for the treatment of insulin reisistance and type 2 diabetes
ZA984084B (en) Use of thiazolidinedione derivatives in the treatment of polycistic ovary syndrome gestational diabetes and disease states at risk for progressing to noninsulindependent diabetes mellitus
AU2003236521A8 (en) Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
HUP0200929A3 (en) Thiazolidinedione derivative and its use as antidiabetic and process for preparation thereof
HUP0200937A2 (en) Thiazolidinedione derivative and its use as antidiabetic and process for preparation thereof
HUP0003260A3 (en) Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin
HK1028200A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
HK1029272A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
IL112967A0 (en) Pharmaceutical compositions comprising a complex carbohydrate to diminish hypoglycemia in patients with diabetes mellitus
GB0210357D0 (en) Methods for regulating blood glucose and appetite suppression in type 2 diabetics
HRP20010770B1 (en) Thiazolidinedione derivative and its use as antidiabetic
AP2001002332A0 (en) Thiazolidinedione derivative and its use as antidiabetic
GB2355189B (en) Herbal preparation for the treatment of diabetes mellitus
IL153279A0 (en) Thiazolidinedione salt for treatment of diabetes mellitus
AU2382701A (en) Thiazolidinedione derivatives in treatment of diabetes mellitus of type
HUP0002669A3 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
IL143088A0 (en) A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method
GB9928680D0 (en) A method and infant formula for reducing the incidence of insulin-dependent diabetes mellitus type 1 in infants
HUP0700127A3 (en) Pharmaceutical combinations for treatment and of diabetes mellitus
PL385375A3 (pl) Nowe związki, pochodne pirydyny, zawierająca je kompozycja oraz ich farmaceutyczne zastosowanie w powikłaniach układu naczyniowego cukrzycy i związanych z wiekiem
GB9705041D0 (en) Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity
AU6270600A (en) Oligosaccharide metabolites of glycosaminoglycans and their use in the diagnosisand treatment of complications of diabetes